<DOC>
	<DOC>NCT02776371</DOC>
	<brief_summary>Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1), especially 47-66% in China.</brief_summary>
	<brief_title>Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori</brief_title>
	<detailed_description />
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Tinidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Patients who were intend to undergo upper endoscopy for any purpose and volunteered to written inform consent. negative in rapid urease test (RUT) previous standard eradication therapy for H. pylori; history of esophagectomy or gastrectomy; gastrointestinal malignancy; contraindications or allergic to study drugs; user of taking medicine that may affect the result of the study within 4 weeks (e.g., protonpump inhibitors, H2receptor antagonists, bismuth or antibiotics etc.); cardiopulmonary, hepatic or renal insufficiency, and/or severe current diseases or malignancy; pregnant or lactating women; participants of other trial within the past 3 months; unwilling or unable to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Helicobacter pylori</keyword>
	<keyword>Sequential therapy</keyword>
	<keyword>Modified non-clarithromycin triple therapy</keyword>
</DOC>